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monia pathogens, especially respiratory viruses. Indeed, because
of these methods, it is now much easier to conﬁdently diagnose a
viral thanbacterial cause of a respiratory tract infection.Diagnosing
a bacterial aetiology of pneumonia remains problematic, although
may be improved with use of quantitative approaches that are the
focus of ongoing research. There is a pressing need for completely
newapproaches topneumoniadiagnostics, particularlyapproaches
that candistinguish colonising from infectingmicroorganisms, that
can distinguish recent from past infection, that account for host
responsiveness, and can utilise samples that are easy to obtain.
http://dx.doi.org/10.1016/j.ijid.2014.03.461
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Pneumonia remains a leading cause of under-5 childhood mor-
tality, particularly in low andmiddle-income countries. The rollout
of conjugate bacterial vaccines, including Haemophilus inﬂuenzae
type b conjugate vaccine (HibCV) and particularly pneumococ-
cal conjugate vaccine (PCV), into national immunization programs
recently, has been associated with dramatic decline in all-cause
pneumonia hospitalization in many developed countries where
PCV immunizationhas been implemented. Also, PCV immunization
has variably been associated with changes in incidence of hospi-
talization due to inﬂuenza virus and RSV-associated pneumonia
in some settings. There is, however, limited data from low and
middle-income countries on the effectiveness of PCV against pneu-
monia once introduced into immunization programs. A broader
diversity of serotypes associated with pneumococcal disease and
higher prevalence of underlying risk factors for pneumonia such as
greater prevalence of malnutrition, HIV-infection and tuberculosis
may affect the impact of PCV on all-cause pneumonia morbidity
and mortality in children. Furthermore, early experience from few
studies in developed countrieswith 7-valent PCV, suggested a tem-
poral association between PCV-7 introduction and an increase in
complicated pneumonia including that due to empyema due to
few serotypes not included in PCV7, but which are now included in
the 10 and 13-valent PCVs formulations currently used. The global
public health value of PCVwill bemeasured by its success in reduc-
ing all-cause childhood pneumonia morbidity and mortality in low
and middle-income countries. Results on the impact of PCV immu-
nization in early-adopting low and middle incoming countries are
imminent and will contribute in determining the potential of PCV
in improving child health globally.
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The goal of PATH’s pneumococcal vaccine project is to accel-
erate the development of promising new pneumococcal vaccines
that are safe and effective in young children, and to ensure their
affordability, availability, and use in developing countries. As part
of this project, we are developing a portfolio of vaccine candi-
dates with a particular emphasis on common protein vaccines.
Vaccines containing proteins that are common to all pneumococ-
cal serotypes could provide broad and affordable protection to
children worldwide. Our lead protein vaccine strategy involves
the development of an inactivated, whole cell vaccine (SPWCV)
designed to offer broad serotype-independent coverage coupled
with low manufacturing costs. Preclinical studies have demon-
strated protection against both nasopharyngeal carriage (T-cell
mediated) and invasive disease (antibody mediated). We recently
completed a randomized, double blind, placebo-controlled Phase 1
study designed to assess the safety, tolerability and immunogenic-
ity of SPWCV formulated with aluminum hydroxide (PATH-wSP)
in healthy adults. PATH-wSP was found to be safe and well toler-
ated. PATH-wSPelicited signiﬁcant immunoglobulinG responses to
pneumococcal antigens, including pneumococcal surface protein A
(PspA) and pneumolysin, as measured by a variety of immunoas-
says, including enzyme-linked immunosorbent assay (ELISA) and
Meso Scale Discovery (MSD) multiplex assay. Functional antibody
responses were detectable by either passive transfer of protection
tomice or elicitation of pneumolysin toxin neutralizing antibodies.
Signiﬁcant increases in T-cell cytokine responses, including IL-17,
were seen among subjects receiving the 600g dose level of PATH-
wSP.
We are also exploring strategies to incorporate commonprotein
antigens into a limited-valency pneumococcal conjugate vaccine
(PCV). This hybrid approach is designed to take advantage of the
regulatory path established for licensure of new PCVs and to offer
the further beneﬁt of broader coverage by adding a pneumococ-
cal protein antigen. Overall, pneumococcal protein vaccines offer
considerable promise, either alone or in combination with PCVs;
yet the clinical and regulatory challenges for eventual licensure are
considerable.
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